PubMed
Ciliary neurotrophic factor (CNTF) and related peptides in neuroprotection
Peterson WM, Wang Q, Tzekova R, et al. Prog Retin Eye Res. 2013
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 43% · Mixed 42% · Unfavorable overall 15%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.1–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 53% said they felt similar to their last entry, 35% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 281 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 25–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 329 repeat reporters
Published sources linked on the P21 and TB-500 Fragment wiki pages.
PubMed
Peterson WM, Wang Q, Tzekova R, et al. Prog Retin Eye Res. 2013
PubMed
Ghasemi M, Alizadeh E, Motlagh BF, et al. Cell biochemistry and function. 2021
PubMed
Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026